Clinical trials: PET-CT
Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer
This phase IV trial studies how well an investigational scan (18F-fluciclovine PET-CT) works for the measurement of therapeutic response in patients with prostate cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT04134208
- Testing
- Computed Tomography, Fluciclovine F18, Positron Emission Tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Prostatic Neoplasms, Prostate Cancer
18F-DCFBC PET/CT in Prostate Cancer
Background: Prostate cancer is the second leading cause of cancer deaths in American men. A chemical called a radiotracer helps doctors get images of this type of cancer.
- Trial name
- NCT02190279
- Testing
- 18F DCFBC, Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone
Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
This trial studies how well fluciclovine 18F PET/CT imaging works in assessing hormone-naive men with prostate cancer that has spread to the bone. Fluciclovine 18F is a radioactive drug used to measure tumor growth.
- Conditions
- Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
- Trial name
- NCT03707184
- Testing
- Computed Tomography, Fluciclovine F18, Positron Emission Tomography
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Utah
Psoriasis, Cardiovascular Disease
Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
The VIP-U Study is a clinical trial designed to investigate the effect of ustekinumab (Stelara) and placebo on reducing vascular inflammation and cardiometabolic risk biomarkers in patients with moderate to severe psoriasis.
- Trial name
- VIP-U (NCT02187172)
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Pennsylvania
Cholecystitis
FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis
This is a pilot study to investigate the ability of fluorodeoxyglucose-positron emission tomography (FDG-PET) and Positron emission tomography-computed tomography (PET/CT) as a direct method of detecting infection and/or…
- Trial name
- NCT00590395
- Testing
- 18FDG (an FDA-approved radiopharmaceutical)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Alan D. Waxman, M.D.
Non-Hodgkin's Lymphoma
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
This research is being done to see if a PET scan that is obtained after 3 cycles of a standard chemotherapy regimen can help guide treatment for patients with a blood disease called Non-Hodgkin's Lymphoma.
- Trial name
- NCT00809341
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Liver Cancer, Hepatic Tumors
Follow-up Yttrium-90 Internal Pair Production PET/CT vs Brehmsstrahlung Imaging in Patients With Primary/Metastatic Liver Tumors
This is a prospective non-blinded case series involving the acquisition of a pair production PET/CT as soon as possible after an already performed Y-90 Sirspheres treatment of hepatic malignancy.
- Trial name
- NCT02202317
- Testing
- PET/CT Scan
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Miami
Prostate Cancer
18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer
The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in Veterans.
- Trial name
- PROSPYL (NCT04390880)
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Neuroendocrine Tumors, Von Hippel-Lindau Syndrome
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
Background: Neuroendocrine tumors (NETs) are rare but have been more common over the past decade. The only treatment for NETs is surgery, but most are found when they are too advanced for surgery.
- Conditions
- Neuroendocrine Tumors, Von Hippel-Lindau Syndrome, Hippel-Lindau Disease
- Trial name
- NCT01967537
- Testing
- 68Gallium DOTATATE, Radio-guided surgery
- Where
- United States
- Volunteers
- 341 people
- Sponsor
- National Cancer Institute (NCI)
Pulmonary Nodule
Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules
RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 (FDG)-PET/CT scan, done before and after steroid therapy may help doctors assess a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00906503
- Testing
- dexamethasone, PET/Computed Tomography (CT), fludeoxyglucose (18F)
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Adenocarcinoma of the Prostate
Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.
- Trial name
- NCT02523924
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Small-Cell-Lung Cancer (NSCLC)
Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients
The purpose of this study is to help researchers investigate if a new imaging agent named 18F-FMISO can predict if patients with lung cancer will respond to standard therapy, as well as whether disease will reoccur in the future.
- Trial name
- NCT02016872
- Testing
- 18F-FMISO, PET/CT
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Flu
PET-CT Scans in Healthy Volunteers After Flu Vaccination
This study is being done to learn how previous flu vaccination or previous infection with flu virus affects the immune response to vaccination.
- Trial name
- Pro00000226 (NCT00769002)
- Testing
- FluShield, FluShield - same arm, FluShield - opposite arm
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Hackensack Meridian Health
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
This phase II trial studies how well gallium Ga 68-labeled gastrin-releasing peptide receptor (GRPR) antagonist BAY86-7548 (68Ga-RM2) positron emission tomography (PET)/computed tomography (CT) works in detecting regional nodal…
- Conditions
- Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma, Stage IV Prostate Adenocarcinoma
- Trial name
- NCT03113617
- Testing
- Computed Tomography, Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Andrei Iagaru
Any Condition With a Clinical Indication for PET/CT Exam
Comparison of 18F FDG PET/CT TO PET MRI
The objective of this study is to gather image and associated data to of a pre-market PET/MRI scanner and to use the data for regulatory submission and future product development and marketing.
- Trial name
- PET/MR US (NCT01986985)
- Testing
- PET/MRI system
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- GE Healthcare
Bone Cancer
Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer
This clinical trial studies fluorine F-18 sodium fluoride positron emission tomography (PET)/computed tomography (CT) in diagnosing bone tumors in patients with cancer.
- Trial name
- NCT01541358
- Testing
- fluorine F 18 sodium fluoride, positron emission tomography/computed tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stanford University
Invasive Lobular Breast Carcinoma
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
FES PET/CT imaging for invasive lobular cancer
- Trial name
- NCT04252859
- Testing
- [18F]Fluoroestradiol (FES) PET/CT
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Utah
Non-Small Cell Lung Cancer
A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
This is a single-arm, open-label, multicenter, international pilot study to evaluate changes that occur in 2-deoxy-2-[18F]fluoro-D-glucose (FDG)- and 3'-deoxy-3'-[18F]fluorothymidine(FLT)-PET (Positron Emission Tomography)…
- Trial name
- NCT00453362
- Testing
- 2-deoxy-2-[18F]fluoro-D-glucose (FDG), 3'-deoxy-3'-[18F]fluorothymidine (FLT), erlotinib HCl
- Volunteers
- 88 people
- Sponsor
- Genentech, Inc.
Oral Cavity Squamous Cell Carcinoma
Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer
This clinical trial studies how well helical computed tomography (CT), positron emission tomography (PET)/CT, magnetic resonance imaging (MRI), and cone beam computed tomography (CBCT) work alone or in combination in predicting…
- Trial name
- NCT03053960
- Testing
- Computed Tomography, Positron Emission Tomography and Computed Tomography Scan, Cone-Beam Computed Tomography
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Recurrent Melanoma, Stage IIIA Melanoma
FDG-PET in Advanced Melanoma
This clinical trial studies how well FDG-PET/CT measures early response in patients with stage III-IV melanoma who are receiving chemotherapy.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT02236546
- Testing
- [18F]fluorodeoxyglucose, Molecular assays on biopsied tissue, positron emission tomography
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Vanderbilt-Ingram Cancer Center